Cardiovascular benefit : Wegovy is currently the only weightmanagement injection licensed to reduce cardiovascular event risk in people with obesity and heart disease
Immediate medical attention (emergency department or urgent care) is warranted for: Signs of anaphylaxis or severe allergic reaction, including difficulty breathing, throat tightness, rapid pulse, dizziness, or widespread urticaria (call 911) Severe swelling extending beyond the injection site or involving the face, lips, or tongue Signs of significant infection, including fever above 100.4F (38C), purulent drainage, or rapidly spreading erythema with warmth Severe pain disproportionate to visible findings Skin necrosis, blistering, or ulceration at the injection site Scheduled healthcare provider evaluation is appropriate for: Persistent injection site reactions lasting more than 5 to 7 days despite conservative management Recurrent moderate to severe reactions with each injection, suggesting possible hypersensitivity Development of indurated nodules or lipohypertrophy at injection sites Uncertainty about whether symptoms represent normal reactions or require intervention Clinical assessment of concerning injection site reactions typically includes examination of the affected area, review of injection technique, and evaluation for signs of infection or hypersensitivity
Nausea (Feeling Sick) Nausea is the most common side effect of semaglutide
Dietary Changes: Focus on high-protein, fiber-rich foods to enhance satiety
Consult a qualified healthcare professional before starting any prescription treatment
Who Can Benefit from AOD 9604
